| INTRODUCTION
Tacrolimus is an immunosuppressive agent that is used for the prevention and treatment of graft rejection in organ transplant recipients and is used in combination with drugs such as steroids and mycophenolate mofetil. [1] [2] [3] [4] Tacrolimus has a narrow therapeutic index and high inter-and intra-individual pharmacokinetic and pharmacodynamic variability. 3, 5, 6 Elevated serum concentrations of tacrolimus may cause clinically significant adverse effects such as nephrotoxicity, neurotoxicity, and hyperglycemia; therefore, therapeutic drug monitoring (TDM)
is important to balance efficacy and safety. 6 However, the therapeutic range of tacrolimus is set differently based on the transplantation organ, age, and immunosuppression protocol used by the researcher.
In addition, blood concentrations of tacrolimus have been reported to vary between laboratories based on the assay platform used. [7] [8] [9] [10] [11] Tacrolimus concentration has been measured using various commercial assays that use immunoassay principles, including the fluorescence polarization immunoassay, microparticle enzyme immunoassay, enzyme multiplied immunoassay, radioimmunoassay, enzyme-linked immunosorbent assay, high-performance liquid chromatography-ultraviolet detection (HPLC-UV), and liquid chromatography-tandem mass spec-
trometry (LC-MS/MS). Because the LC-MS/MS method has low cross-
reactivity with the tacrolimus metabolite, this method exhibits higher specificity and selectivity than immunoassays. It also has the advantage of simultaneous measurement with other immunosuppressive drugs such as everolimus and sirolimus and is considered the gold standard analytical method for TDM. 4, [12] [13] [14] [15] However, this method has a few limitations such as complex sample processing that requires skilled experts and a high cost for the initial laboratory setup. Therefore, the immunoassay method, which can be automated and is capable of handling multiple specimens, is widely used in laboratories. 14, 16, 17 The TAC assay of the Dimension platform has been widely used in clinical laboratories due to prompt reporting by reduced manual specimen pretreatment. 18 The Dimension TAC assay (Siemens Healthcare Diagnostics, Tarrytown, NY, USA) is based on the affinity chrome-mediated immunoassay (ACMIA) and is an upgraded reagent found in the existing Dimension TACR assay (Siemens Healthineers, USA). 19 In this study, we evaluated the performance of the Dimension TAC assay and identified possible correlations with other assay platforms.
| MATERIALS AND METHODS

| Laboratory measurements
Blood tacrolimus concentrations were measured using reagents from the Dimension TAC assay and Dimension TACR assay on a 
| Precision studies
The evaluation of assay precision was based on the Clinical and Laboratory Standards Institute (CLSI) guideline EP5-A2. 20 Quality control (QC) materials corresponding to three assay concentrations (lot no. 33080) were used. Two replicates of each control sample were analyzed twice a day for 20 days, with the two runs separated by at least 2 hours. The mean of each concentration, standard deviation, within-run coefficient of variation (CV), and total CV were calculated.
| Linearity
We referred to the CLSI guideline EP6-A for linearity measurements. 21 Patient samples were serially diluted to five concentrations ranging from low to high, based on the measurable range as described by the manufacturer. Each concentration was measured four times.
For each concentration, the mean measured value was compared to the expected value.
| Comparison studies
The evaluations of assay methods were based on the CLSI guideline EP9-A3. 22 From October 2015 to January 2016, we obtained samples from heart-lung transplantation (HLT), kidney transplantation (KT), and liver transplantation (LT) patients taking tacrolimus.
Whole blood samples were collected from patients with a clinically significant concentration range. Sixty samples were analyzed using different test methods according to the transplanted organ. Deming regression was used to calculate slope, intercept, and correlation coefficient (R value).
| Detection capability
The detection limits were evaluated based on the CLSI guideline EP17-A2. 23 The limit of blank (LoB) was determined by measuring the mean and standard deviation of 20 repeated measurements using a zero-level calibrator as a blank sample. Pooled EDTA whole blood samples were used to determine the limit of detection (LoD).
The limit of quantification (LoQ), defined as the minimum concentration with a CV < 20%, was determined by repeated measurements for 20 days with one run. Target concentrations were approximately 1.0, 1.5, 2.0, 2.5, and 3.5 ng/mL. For each concentration, pooled EDTA whole blood samples were aliquoted into 20
samples.
| Lot-to-lot reagent variation
We referred to the CLSI guideline EP26-A for evaluation of lot-to-lot reagent variation. 24 Samples from 42 patients were used to evaluate three reagent lots (lot 1, FB6062; lot 2, GB6160; and lot 3, GC6300).
The correlation coefficient (R value) was calculated by Deming regression, and percent difference values between lots were calculated using the following formulas
| Carryover
High-and low-concentration samples were prepared. After four consecutive measurements of high-concentration samples (H1, H2, H3, and H4), the low-concentration samples (L1, L2, L3, and L4)
were measured four times consecutively. The carryover between Percent difference = {(mean1 − mean2)∕mean1 × 100(%)} samples (%) was calculated as {L1−(L3 + L4)} × 100/{(H3 + H2)/2− (L3 + L4)/2}, 25 and the acceptable limit was set at 5% or less. 
| Statistical analyses
| RESULTS
| Precision studies
For each concentration, the mean, standard deviation, within-run CV, and total CV are summarized in Table 1 . The total CV of low-, medium-, and high-concentration QC materials was 7.3%, 5.1%, and 5.7%, respectively. The CV of low-concentration material was higher than that of high-concentration material.
| Evaluation of linearity
The linear range, the range at which the coefficient of determination
) is slightly greater than 0.99, was 1.6−31.7 ng/mL ( Figure 1 ).
| Comparison studies
Comparisons between the Dimension TAC assay, Dimension TACR assay, Architect Tacrolimus assay, Elecsys Tacrolimus assay, and
MassTrak LC-MS/MS Tacrolimus kit are shown in Table 2 and Figures 2 and 3. In the all samples, the R value was greater than .90 in the comparison between the Dimension TAC assay and Dimension TACR assay, Elecsys assay. In the HLT group, the R values were all .90 or greater. In the KT group, the R value was less than .90, except for the Dimension TACR assay. In the LT group, the R value was greater than .90 only in the comparison between the Dimension TACR assay and Elecsys assay.
In all organ transplant patients, the tacrolimus concentration was lowest
when measured with the MassTrak LC-MS/MS Tacrolimus kit method.
| Detection capability
The mean results for LoB and LoD were 0.119 and 0.837 ng/mL, respectively. The LoB was 0.287 ng/mL, and the LoD was 0.469 ng/mL.
The LoD was smaller than the lower limit of the measurement range suggested by the manufacturer. The LoQ was 0.808 ng/mL.
| Lot-to-lot reagent variation
The R value between three lots was greater than .975. The percent difference was 6.6% between lots 1 and 2, 9.6% between lots 1 and 3, and 9.9% between lots 2 and 3 ( Figure 4 ).
| Carryover
The carryover between samples was 0.41%.
| DISCUSSION
The total CV% for low-and high-concentration QC materials was 7.3 and 5.7%, respectively, for the Dimension TAC assay, better than the existing Dimension TACR assay, with CV% of 8.1% and 5.9%, respectively, for low-and high-concentration QC materials. 26 Previously,
another study reported a total CV% of 5.9−7.5% for the Dimension TAC assay, consistent with our results. 27 International Association of Therapeutic Drug Monitoring and Clinical Toxicology recommends the imprecision goals of <9% for ACMIA tacrolimus assay. 28 Therefore, the Dimension TAC assay has acceptable precision for clinical use.
The linearity of the assay was excellent, with a slope of 1.000 and an intercept of 0.658 at a clinically significant concentration range.
The LoD and LoQ were lower than 0.7 and 1.0 ng/mL, respectively, which are the values provided by the manufacturer. In this study, the LoQ was 0.808 ng/mL, lower than the value (1.0 ng/mL) suggested by the European Consensus Conference on tacrolimus optimization. 29 These results show that the assay performed sufficiently in measuring low-concentration tacrolimus. In addition, Dimension TAC assay showed better detection capability than the existing Dimension TACR assay. 26 In all transplant recipient samples, the tacrolimus concentration measured using the MassTrak LC-MS/MS Tacrolimus kit was lower than that measured using the Dimension TAC assay. In the range of 1.0−15.0 ng/ mL, the mean bias between the two methods was 1.39 ng/mL. This finding is consistent with previous studies that showed higher levels in the immunoassay due to cross-reactivity between the antibody and tacrolimus metabolites. In our study, the immunoassay methods always yielded a slightly higher tacrolimus concentration compared to MassTrak (mean bias 1.18−2.65 ng/mL) in all transplant groups. In a study that compared MassTrak to the Architect immunoassay, the mean bias was 0.81 ng/mL; however, in this study, the mean bias was higher than that of the Architect immunoassay. The differences in mean values among the three reagent lots tested were less than 10%. According to a 3-year survey of the immunosuppressive drug by the College of American Pathologists, the mean tacrolimus concentration increased stepwise every year due to changes in the immunoassay reagent. 41 In addition, based on a previous report of lot-to-lot reagent comparability for α-fetoprotein, ferritin, and CA19-9, the percent differences ranged widely from 0.1% to 18.6%. 42 In many laboratories, the typical tolerance limit was ≤10% between reagent lots. Because tacrolimus is a drug used for maintenance of immunosuppression after transplantation, it is necessary to not only continuously monitor tacrolimus concentration but also to obtain consistent results. 41, 43, 44 Dimension TAC assay showed lot-tolot consistency when applying the tolerance limit commonly used; this is advantageous because consistency of results can be obtained for a substantial period of time.
The bioavailability and pharmacogenetics of tacrolimus between transplant patients are highly variable; therefore, precise and accurate results are important. It is also important to maintain tacrolimus blood levels because it has a narrow therapeutic range, and efficacy and toxicity are associated with trough levels. However, standardization of tacrolimus assay platforms has not yet been established, resulting in interlaboratory variability in results. 29 The results should be consistent in one clinical laboratory to avoid the inappropriate clinical interpretation of each patient results. The Dimension TAC assay showed better precision, linearity, detection capability, and minimal lot-to-lot reagent variability than existing Dimension TACR assay. These performances can be attributed to ensure consistent results. And, this assay was comparable with other tacrolimus assays, similar to existing assay.
New assay reagent is based on the ACMIA method, and advantages include ease of testing, convenience, and faster reporting times due to a fully automated process from pretreatment to analysis. Although there have been many studies on tacrolimus TDM, our study compared different platforms based on the type of transplanted organ; therefore, this study may provide some useful information regarding which test method to use. We believe the Dimension TAC assay may be suitable for TDM of transplant patients.
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